Who are Short term androgen deprivation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ADT, Androgen Suppression Therapy, Long term androgen deprivation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/short-term-androgen-deprivation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Short term androgen deprivation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Short term androgen deprivation (Short term androgen deprivation) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen deprivation therapy (ADT). Area: Oncology.

phase 3 Androgen deprivation therapy (ADT) Androgen receptor / testosterone production Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Short term androgen deprivation (Short term androgen deprivation) — Fundación de Investigación Biomédica - Hospital Universitario de La Princesa. Short-term androgen deprivation therapy (ADT) temporarily suppresses testosterone production to slow or stop the growth of androgen-dependent prostate cancer cells.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Short term androgen deprivation TARGET	Short term androgen deprivation	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	phase 3	Androgen deprivation therapy (ADT)	Androgen receptor / testosterone production
ADT	ADT	Canadian Cancer Trials Group	phase 3	Androgen deprivation therapy	Androgen receptor / testosterone production
Androgen Suppression Therapy	Androgen Suppression Therapy	Proton Collaborative Group	phase 3	Androgen deprivation therapy (ADT)	Androgen receptor pathway / testosterone / DHT
Long term androgen deprivation	Long term androgen deprivation	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	phase 3	Androgen deprivation therapy (ADT)	Androgen receptor signaling pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen deprivation therapy (ADT) class)

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · 2 drugs in this class
Proton Collaborative Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Short term androgen deprivation — Competitive Intelligence Brief. https://druglandscape.com/ci/short-term-androgen-deprivation. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab